press releases

605 active patients on Optune therapy at 2015 year end, an increase of 169 percent compared to 2014 year end Publication of EF-14 phase 3 pivotal trial results in the Journal of the American Medical Association concludes adding TTFields to maintenance temozolomide chemotherapy significantly extends progression-free and… Read More

February 23, 2016 07:00 AM Eastern Standard Time ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure will present at Cowen and Company 36th Annual Health Care Conference on March 7, 2016, in Boston. William Doyle, Novocure’s Executive Chairman, will speak on behalf of the company and address questions from analysts. Read More

Health insurance plans covering more than 97 million Americans now provide positive coverage of Optune February 12, 2016 07:00 AM Eastern Standard Time ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ:NVCR) announced today that Anthem, Inc. now covers Optune for members who have newly diagnosed glioblastoma (GBM). Anthem,… Read More

February 09, 2016 11:21 AM Eastern Standard Time ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure’s (NASDAQ: NVCR) phase 3 pivotal clinical trial results of Tumor Treating Fields (TTFields) in combination with temozolomide in newly diagnosed glioblastoma (GBM) have been selected for inclusion in the American Society of Clinical Oncology’s… Read More

February 01, 2016 04:35 PM Eastern Standard Time ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) will hold a conference call and webcast to discuss its fourth quarter and full-year 2015 financial results at 5 p.m. EST on Feb. 29, 2016. Schedule for press release… Read More

Progression free survival and overall survival of patients treated with Tumor Treating Fields combined with gemcitabine were more than double those of gemcitabine-treated historical controls Of the evaluable tumors, 30 percent had partial response and another 30 percent had stable disease January 19, 2016… Read More

555 prescriptions were received in the fourth quarter of 2015, an increase of 108% versus the prior year quarter 603 active patients at December 31, 2015, an increase of 168% versus December 31, 2014 January 11, 2016 07:30 AM Eastern Standard Time ST. HELIER, Jersey–(… Read More

January 07, 2016 04:15 PM Eastern Standard Time ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) announced today that it submitted a premarket approval (PMA) partial amendment application to the Japanese Pharmaceuticals and Medical Devices Agency (PMDA) for the use of Optune, a Tumor Treating Fields (TTFields) therapy delivery device,… Read More

Second generation Tumor Treating Fields delivery system is more than 50 percent lighter and 50 percent smaller than first generation Optune January 06, 2016 08:24 AM Eastern Standard Time ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) filed a premarket approval (PMA) supplement application for its new,… Read More